Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats

Acta Pharmacologica Sinica

Volumn 26, Issue 11, 2005, Pages 1303-1308

  Shen, Fu Ming ^a   Xie, He Hui ^a   Ling, Gang ^a   Xu, Li Ping ^a   Su, Ding Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Amlodipine; Atenolol; Blood pressure; Blood pressure variability; Hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CARBOXYMETHYLCELLULOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG POTENTIATION; HEART CYCLE; MALE; NONHUMAN; PROBABILITY; RAT; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HEART RATE; HYPERTENSION, RENOVASCULAR; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 27744500630     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00185.x     Document Type: Article

References (26)

1. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983; 53: 96-104.
2. Su DF, Cerutti C, Barres C, Vincent M, Sassard J. Blood pressure and baroreflex sensitivity in conscious hypertensive rats of Lyon strain. Am J Physiol 1986; 251: H1111-7.
3. Miao CY, Shen FM, Su DF. Blood pressure variability is increased in genetic hypertension and L-NAME-induced hypertension. Acta Pharmacol Sin 2001; 22: 137-40.
4. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5: 93-8.
5. Mancia G, Frattola A, Parati G, Santucciu C, Ulian L. Blood pressure variability and organ damage. J Cardiovasc Pharmacol 1994; 24: S6-11.
6. Su DF, Miao CY. Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 2001; 28: 709-15.
7. Du WM, Miao CY, Liu JG, Shen FM, Yang XQ, Su DF. Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 41: 233-9.
8. Xie HH, Miao CY, Liu JG, Su DF. Importance of blood pressure variability in organ protection in spontaneously hypertensive rats treated with combination of nitrendipine and atenolol. Acta Pharmacol Sin 2002; 23: 1199-204.
9. Lu ZA, Xie HH, Xu LP, Yin AF, Miao CY, Su DF. Restoration of arterial baroreflex function contributes to organ protection in spontaneously hypertensive rats treated with long-term hydrochlorothiazide mixture. Clin Exp Pharmacol Physiol 2003; 30: 49-54.
10. Xie HH, Miao CY, Jiang YY, Su DF. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. J Hypertens 2005; 23: 193-201.
11. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-21.
12. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, [published erratum appears in Arch Intern Med 1998; 158: 573] Arch Intern Med 1997; 157: 2413-46.
13. Guan S, Fox J, Mitchell KD, Navar LG. Angiotensin and angiotensin-converting enzyme tissue levels in two-kidney, one clip hypertensive rats. Hypertension 1992; 20: 763-7.
14. Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin 2004; 25: 146-7.
15. Su DF, Xu LP, Miao CY, Xie HH, Shen FM, Jiang YY. Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats. Acta Pharmacol Sin 2004; 25: 148-51.
16. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4.
17. Sica DA. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs 1994; 48: 16-24.
18. Prisant LM. Fixed low-dose combination in first-line treatment of hypertension. J Hypertens 2002; 20: S11-9.
19. Moser M. Current recommendations for initial therapy in hypertension: are they still valid? Introduction. Am J Hypertens 1998; 11: 69S-72S.
20. Moser M, Black HR. The role of combination therapy in the treatment of hypertension. Am J Hypertens 1998; 11: 73S-78S.
21. Shan ZZ, Dai SM, Su DF. Relationship between baroreceptor reflex function and end-organ damage in spontaneously hypertensive rats. Am J Physiol 1999; 277: H1200-6.
22. Su DF, Miao CY. Reduction of blood pressure variability: a new strategy for treatment of arterial hypertension. Trends Pharmacol Sci 2005; 26: 388-90.
23. Weir MR. The rationale for combination versus single-entity therapy in hypertension. Am J Hypertens 1998; 11: 163S-169S.
24. Suzuki H, Moriwaki K, Kanno Y, Nakamoto H, Okada H, Chen XM. Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report. Hypertens Res 2001; 24: 153-8.
25. Waeber B, Detry JM, Dahlof B, Puig JG, Gundersen T, Hosie J, et al. Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy? Am J Hypertens 1999; 12: 915-20.
26. Menard J. Critical assessment of combination therapy development. Blood Press 1993; 1 Suppl: 5-9.